SQUADRON CAPITAL MANAGEMENT LLC
Q3 2026 Form 13-F

WESTMONT, DELAWARE
CIK 0002050709 · CRD 334296 · SEC-registered investment adviser
$398.5M Reported Value Total

SQUADRON CAPITAL MANAGEMENT LLC reports 2 total accounts under management (AUM). There are 2 discretionary accounts valued at $385,684,763, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $385.7M gross asset value
Hedge Fund: $385.7M
Source: Form ADV filed 2026-06-29
Reported value
$398.5M
Quarter over quarter
-8.5%
Holdings
35
Top-10 concentration
56.6%

Key People

Form ADV owners & control persons
William Fred Blank
PORTFOLIO MANAGER
Matthew Zachary Sesterhenn
HEAD OF RESEARCH
Jared Allan Gandy
CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2026 13F record

Q3 2026 13F filing summary

Q3 2026 Form 13F portfolio summary
Period of report September 30, 2026
Filed November 16, 2026
Form 13F-HR
Reported value $398.5M
Positions 35
Change in reported value +23.7%
New positions 17
Exited positions 16
Position turnover 64.7%
Top-10 concentration 56.6%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
35 $398.5M
Q2 2026 13F
Filed Aug 14, 2026
34 $322.2M
Q1 2026 13F
Filed May 15, 2026
30 $272.9M
Q4 2025 13F
Filed Feb 17, 2026
29 $236.0M

Top 20 holdings · Q3 2026

Largest Q3 2026 13F positions by reported value
# Holding Reported value % of portfolio
1 KOD KODIAK SCIENCES INC $39.8M 9.99%
2 CCCC C4 THERAPEUTICS INC $31.0M 7.79%
3 COGT COGENT BIOSCIENCES INC $29.3M 7.35%
4 KOD C KODIAK SCIENCES INC $25.6M 6.42%
5 SLN SILENCE THERAPEUTICS PLC $22.8M 5.72%
6 ZNTL ZENTALIS PHARMACEUTICALS INC $18.9M 4.75%
7 EWTX EDGEWISE THERAPEUTICS INC $17.3M 4.33%
8 RLAY RELAY THERAPEUTICS INC $14.2M 3.56%
9 ORIC ORIC PHARMACEUTICALS INC $13.5M 3.38%
10 RLMD RELMADA THERAPEUTICS INC $13.2M 3.31%
11 DFTX DEFINIUM THERAPEUTICS INC $12.9M 3.25%
12 PHVS PHARVARIS N V $12.7M 3.18%
13 ANL ADLAI NORTYE GROUP LTD $12.2M 3.07%
14 VERA VERA THERAPEUTICS INC $9.8M 2.47%
15 IVA INVENTIVA SA $8.9M 2.22%
16 IRON C DISC MEDICINE INC $8.8M 2.21%
17 COGT C COGENT BIOSCIENCES INC $8.5M 2.13%
18 AVTX AVALO THERAPEUTICS INC $6.9M 1.73%
19 ACRS ACLARIS THERAPEUTICS INC $6.3M 1.58%
20 RZLT C REZOLUTE INC $5.5M 1.38%

Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Similar Managers

Finding Similar Managers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings